← FDA DRUG APPROVALS

FDA ANDA · ANDA078660

ENOXAPARIN SODIUM

Sponsor: SANDOZ INC

APPLICATION
ANDA078660
TYPE
ANDA
ORIGINAL APPROVAL
2011-11-28
LATEST ACTION
2023-01-05
ROUTE
INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

ENOXAPARIN SODIUMPrescription
ENOXAPARIN SODIUM 300MG/3ML (100MG/ML) · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS

Approval history

2023-01-05Labeling · Supplement 19 · standardAP
2015-12-28Labeling · Supplement 12 · standardAP
2013-10-29Labeling · Supplement 11 · standardAP
2013-01-31Labeling · Supplement 2AP
2011-11-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →